Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all new lung cancer diagnosis. The majority of people with NSCLC are unsuitable for surgery since most patients have metastatic disease at diagnosis. About 60% of brain metastases arise from lung cancer. Therapeutic approaches to brain metastases include surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery, chemotherapy and new biologic agents. Angiogenesis is essential for the development and progression of cancer, and vascular endothelial growth factor (VEGF) is a critical mediator of tumour angiogenesis. One of the targeted approaches most widely studied in the treatment of NSCLC is the inhibition of angiogenesis. Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. Patients with central nervous system (CNS) metastases have initially been excluded from bevacizumab trials for the risk of cerebral haemorrhage as a result of the treatment. Nevertheless, the available data suggest an equal risk of intracranial bleeding in patients with CNS metastases treated with or without bevacizumab therapy. Several other anti-angiogenetic drugs are being investigated in the treatment of advanced NSCLC patients, but results of their activity specifically in CNS metastases are still lacking.
This review will focus on the potential role of bevacizumab and other anti-angiogenetic agents in the treatment of brain metastases from NSCLC.
Keywords: Angiogenesis, bevacizumab, brain metastases, intracranial bleeding, NSCLC, VEGF, small molecules, linear accelerator, Wingless-type, lymphoid enhancer-binding factor, fetal liver kinase-1/kinase domain region, fms-like tyrosine kinase 4, mitogen-activated protein kinase, bevacizumab plus carboplatin and paclitaxel, hazard ratio
Current Cancer Drug Targets
Title: Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Volume: 12 Issue: 3
Author(s): C. Schettino, M. A. Bareschino, A. Rossi, P. Maione, P. C. Sacco, G. Colantuoni, E. Rossi and C. Gridelli
Affiliation:
Keywords: Angiogenesis, bevacizumab, brain metastases, intracranial bleeding, NSCLC, VEGF, small molecules, linear accelerator, Wingless-type, lymphoid enhancer-binding factor, fetal liver kinase-1/kinase domain region, fms-like tyrosine kinase 4, mitogen-activated protein kinase, bevacizumab plus carboplatin and paclitaxel, hazard ratio
Abstract: Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all new lung cancer diagnosis. The majority of people with NSCLC are unsuitable for surgery since most patients have metastatic disease at diagnosis. About 60% of brain metastases arise from lung cancer. Therapeutic approaches to brain metastases include surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery, chemotherapy and new biologic agents. Angiogenesis is essential for the development and progression of cancer, and vascular endothelial growth factor (VEGF) is a critical mediator of tumour angiogenesis. One of the targeted approaches most widely studied in the treatment of NSCLC is the inhibition of angiogenesis. Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. Patients with central nervous system (CNS) metastases have initially been excluded from bevacizumab trials for the risk of cerebral haemorrhage as a result of the treatment. Nevertheless, the available data suggest an equal risk of intracranial bleeding in patients with CNS metastases treated with or without bevacizumab therapy. Several other anti-angiogenetic drugs are being investigated in the treatment of advanced NSCLC patients, but results of their activity specifically in CNS metastases are still lacking.
This review will focus on the potential role of bevacizumab and other anti-angiogenetic agents in the treatment of brain metastases from NSCLC.
Export Options
About this article
Cite this article as:
Schettino C., A. Bareschino M., Rossi A., Maione P., C. Sacco P., Colantuoni G., Rossi E. and Gridelli C., Targeting Angiogenesis for Treatment of NSCLC Brain Metastases, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277476
DOI https://dx.doi.org/10.2174/156800912799277476 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Steroidal Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitor Triggers Pro-apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells
Anti-Cancer Agents in Medicinal Chemistry Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells
Medicinal Chemistry Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Clinical Impact of Gastric Acid Suppressants Use on the Efficacy of Gefitinib in Patients with Advanced Adenocarcinoma of the Lung Harboring Common EGFR Mutations
Clinical Cancer Drugs Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Tumor Initiating Cells
Current Pharmaceutical Biotechnology The Role of Angiogenesis as a Prognostic Factor of Breast Cancer: Recent Review
Current Women`s Health Reviews Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Synthesis and Activity of Epothilone D
Current Drug Targets Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Ent-11α-Hydroxy-15-Oxo-Kaur-16-en-19-Oic-Acid Induces Apoptosis of Human Malignant Cancer Cells
Current Drug Targets Synthesis of Metronidazole Derivatives Containing Pyridine Ring and Anticancer Activity
Letters in Organic Chemistry